Cure My Disease

Don't miss your cure!

 Log in / Sign up

Skin markers may reveal how light therapy fights vitiligo

NCT ID NCT07796893

Knowledge-focused Sponsor: Amany El-Agamy Ibrahim El-Samadony Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 04, 2026 · Updated 3 times

Summary

This study looks at whether a common light treatment for vitiligo changes certain proteins in the skin. Researchers will measure two markers, CD63 and CD9, in skin samples from 20 people with vitiligo before and after three months of narrow-band ultraviolet B (NB-UVB) therapy. They will compare these samples with healthy skin to see if the markers relate to how well the treatment works. The goal is to better understand the biological changes behind repigmentation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Narrow-band ultraviolet B (NB-UVB) phototherapy
What this could lead to
If the markers change with treatment, they could become a way to measure how well NB-UVB therapy is working in vitiligo.
What could go wrong
This is a small, early study with only 20 participants, so the results may not apply to everyone. The markers are being tested as indicators, not as a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

May 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients already diagnosed with vitiligo clinically and by dermoscopy. * Patients who did not receive any treatment for vitiligo for 3 months before joining the study. * Patients who accepted to be enrolled in the study and signed an informed consent. Exclusion Criteria: * Pregnant or lactating females. * Patients with allergy to local anesthesia. * Patients with a history of chronic debilitating diseases, autoimmune disorders, or other systemic diseases. * Patients with other dermatological diseases. * Patients with a history of bleeding disorders or receiving anticoagulant therapy. * Patients with a history of keloid or abnormal scar formation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vitiligo are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vitiligo

Contacts and locations

Locations

  • Tanta University Hospitals

    Tanta, Gharbia Governorate, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.